This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
This article explains what Dividend Aristocrats Etf represents, its strategy, and how it can complement a balanced, income-focused investment plan.
7,686 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
As we reach the halfway point of 2026, certain S&P 500 members are leading the pack with impressive gains. This artic...
Stellantis faces a tougher profitability and cash-flow comparison with its peers. But for patient investors, the long...
WD-40 has evolved from a single iconic spray into a disciplined maintenance-products company. This deep dive explains...
Two heavyweight banks reported solid Q4 2025 results, but investors remain focused on dividends, buybacks and how eac...
Constellation Energy will release its annual guidance in March, but its shares rose to a six-week high on Tuesday as ...
B&G Foods is in the spotlight as its stock roars higher. This article explains the mix of quarterly results, strategi...
Freightcar America (Rail) earnings can signal the health of a cyclical market. This guide breaks down the numbers, si...
Volatile markets point to timeless value: durable, cash-flow engines that actually build stuff. Here are three indust...
PennantPark pays an about 20% yield through an $0.08 monthly payout, but a spillover reserve backs part of the divide...
Radian Group's Q1 2026 earnings narrative reveals how the mortgage insurance business is performing, how risk is mana...
Beasley (BBGI) has a unique mix of local radio and digital assets. This guide breaks down what to watch in the 2025 e...